Table of Contents
ISRN Oncology
Volume 2013, Article ID 252318, 4 pages
http://dx.doi.org/10.1155/2013/252318
Research Article

CD79B and MYD88 Mutations in Splenic Marginal Zone Lymphoma

1Department of Pathology, Oslo University Hospital, The Norwegian Radium Hospital, 0310 Oslo, Norway
2Faculty of Medicine, University of Oslo, 0316 Oslo, Norway

Received 16 November 2012; Accepted 11 December 2012

Academic Editors: M. Emoto, N. A. Franken, H. Zhang, and J. M. Zidan

Copyright © 2013 Gunhild Trøen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. H. Swerdlow, E. Campo, N. L. Harris et al., WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Lyon, France, 4th edition, 2008.
  2. B. Kahl and D. Yang, “Marginal zone lymphomas: management of nodal, splenic, and MALT NHL,” Hematology, vol. 2008, no. 1, pp. 359–364, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. P. Algara, M. S. Mateo, M. Sanchez-Beato et al., “Analysis of the IgV(H) somatic mutations in splenic marginal zone lymphoma defines a group of unmutated cases with frequent 7q deletion and adverse clinical course,” Blood, vol. 99, no. 4, pp. 1299–1304, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. C. Kalpadakis, G. A. Pangalis, E. Dimitriadou et al., “Mutation analysis of IgVH genes in splenic marginal zone lymphomas: correlation with clinical characteristics and outcome,” Anticancer Research, vol. 29, no. 5, pp. 1811–1816, 2009. View at Google Scholar · View at Scopus
  5. K. Stamatopoulos, C. Belessi, T. Papadaki et al., “Immunoglobulin heavy- and light-chain repertoire in splenic marginal zone lymphoma,” Molecular Medicine, vol. 10, no. 7–12, pp. 89–95, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. A. A. Alizadeh, M. B. Eisen, R. E. Davis et al., “Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling,” Nature, vol. 403, no. 6769, pp. 503–511, 2000. View at Publisher · View at Google Scholar · View at Scopus
  7. R. E. Davis, K. D. Brown, U. Siebenlist, and L. M. Staudt, “Constitutive nuclear factor κB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells,” Journal of Experimental Medicine, vol. 194, no. 12, pp. 1861–1874, 2001. View at Publisher · View at Google Scholar · View at Scopus
  8. R. Küppers, U. Klein, I. Schwering et al., “Identification of Hodgkin and Reed-Sternberg cell-specific genes by gene expression profiling,” The Journal of Clinical Investigation, vol. 111, no. 4, pp. 529–537, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. E. Ruiz-Ballesteros, M. Mollejo, A. Rodriguez et al., “Splenic marginal zone lymphoma: proposal of new diagnostic and prognostic markers identified after tissue and cDNA microarray analysis,” Blood, vol. 106, no. 5, pp. 1831–1838, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. P. J. Jost and J. Ruland, “Aberrant NF-κB signaling in lymphoma: mechanisms, consequences, and therapeutic implications,” Blood, vol. 109, no. 7, pp. 2700–2707, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Compagno, W. K. Lim, A. Grunn et al., “Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma,” Nature, vol. 459, no. 7247, pp. 717–721, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. G. Lenz, R. E. Davis, V. N. Ngo et al., “Oncogenic CARD11 mutations in human diffuse large B cell lymphoma,” Science, vol. 319, no. 5870, pp. 1676–1679, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. R. E. Davis, V. N. Ngo, G. Lenz et al., “Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma,” Nature, vol. 463, pp. 88–92, 2010. View at Publisher · View at Google Scholar
  14. V. N. Ngo, R. M. Young, R. Schmitz et al., “Oncogenically active MYD88 mutations in human lymphoma,” Nature, vol. 470, no. 7332, pp. 115–119, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. D. Rossi, S. Deaglio, D. Dominguez-Sola et al., “Alteration of BIRC3 and multiple other NF-{kappa}B pathway genes in splenic marginal zone lymphoma,” Blood, vol. 118, no. 18, pp. 4930–4934, 2011. View at Publisher · View at Google Scholar
  16. Y. Yan, Y. Huang, A. J. Watkins et al., “BCR and TLR signalling pathways are recurrently targeted by genetic changes in splenic marginal zone lymphomas,” Haematologica, vol. 97, no. 4, pp. 595–598, 2012. View at Publisher · View at Google Scholar
  17. U. Novak, A. Rinaldi, I. Kwee et al., “The NF-κB negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas,” Blood, vol. 113, no. 20, pp. 4918–4921, 2009. View at Publisher · View at Google Scholar · View at Scopus